Protalix BioTherapeutics, Inc. (PLX): Shareholders' Equity
$48.23M
As of 2025-12-31
$71.40M
As of 2026-06-30
+16.1%
10-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $48.23M | +11.6% | 2026-03-18, Balance as of period end |
| 2024-12-31 | $43.21M | +28.7% | 2026-03-18, Balance as of period end |
| 2023-12-31 | $33.57M | n/m | 2026-03-18, Balance as of period end |
| 2022-12-31 | -$10.64M | n/m | 2025-03-17, Balance as of period end |
| 2021-12-31 | -$6.04M | n/m | 2024-03-14, Balance as of period end |
| 2020-12-31 | -$27.04M | n/m | 2023-02-27, Balance as of period end |
| 2019-12-31 | -$70.32M | n/m | 2022-03-31, Balance as of period end |
| 2018-12-31 | -$52.88M | n/m | 2021-03-30, Balance as of period end |
| 2017-12-31 | -$29.46M | n/m | 2020-03-12, Balance as of period end |
| 2016-12-31 | -$9.96M | n/m | 2019-03-18, Balance as of period end |
| 2015-12-31 | $10.87M | n/m | 2018-03-06, Balance as of period end |
| 2014-12-31 | -$55.60M | n/m | 2017-03-16, Balance as of period end |
| 2013-12-31 | -$26.95M | n/m | 2016-03-08, Balance as of period end |
| 2012-12-31 | -$3.36M | n/m | 2015-03-12, Balance as of period end |
| 2011-12-31 | -$26.08M | n/m | 2014-03-13, Balance as of period end |
| 2010-12-31 | -$11.32M | n/m | 2013-02-28, Balance as of period end |
| 2009-12-31 | $15.88M | n/a | 2012-02-27, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Protalix BioTherapeutics, Inc. (PLX) | 2025-12-31 | $48.23M | +11.6% |
| Invivyd, Inc. (IVVD) | 2025-12-31 | $241.54M | +257.6% |
| Champions Oncology, Inc. (CSBR) | 2026-04-30 | $3.94M | +4.4% |
| Fennec Pharmaceuticals Inc. (FENC) | 2025-12-31 | $35.47M | n/m |
| Vir Biotechnology, Inc. (VIR) | 2025-12-31 | $765.28M | -33.5% |
| Editas Medicine, Inc. (EDIT) | 2025-12-31 | $27.29M | -79.7% |
| Voyager Therapeutics, Inc. (VYGR) | 2025-12-31 | $196.08M | -34.6% |
| Black Diamond Therapeutics, Inc. (BDTX) | 2025-12-31 | $112.21M | +34.7% |
| Sangamo Therapeutics, Inc (SGMOQ) | 2025-12-31 | -$14.27M | n/m |
Compare PLX, IVVD, CSBR, FENC side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗